Vitamin D research spans nutritional status, active vitamin D signaling, immune regulation, cell differentiation, stromal biology and outcomes in several cancer populations.
Share your diagnosis, current treatment and the questions you want the clinical team to consider.
Tell us what you are facing and what you hope to understand. The team will follow up personally.
Sunridge considers vitamin D status, calcium balance, kidney function, medications and the cancer plan together. This library distinguishes nutritional vitamin D research from studies of calcitriol and related vitamin D receptor compounds.
Calcitriol and cholecalciferol reduced proliferation and migration and increased apoptosis in breast-cancer models, with added activity alongside raloxifene.
In a prospective cohort of 3,995 women with invasive breast cancer, vitamin D sufficiency was associated with better overall, disease-free and second-primary-cancer-free survival.
Calcitriol or its analogue strengthened growth inhibition and apoptosis when combined with lapatinib or neratinib in breast-cancer models.
A post-hoc AMATERASU analysis found a strong relapse-free-survival signal among colorectal-cancer patients with high soluble CD40 ligand.
The randomized SUNSHINE trial reported a longer median progression-free interval with higher-dose vitamin D3 alongside chemotherapy; adjusted analysis favored the higher-dose group.
Among 1,437 patients with stage III colon cancer, nondeficient vitamin D status was associated with improved disease-free survival, overall survival and time to recurrence.
The AMATERASU randomized trial reported a stronger relapse-free-survival signal in the subgroup whose baseline vitamin D level was 20–40 ng/mL.
Vitamin D3 and calcitriol inhibited leukemia-cell proliferation, promoted G1 arrest and apoptosis and prolonged survival in the reported model.
Vitamin D receptor activation reprogrammed pancreatic tumor stroma, increased intratumoral gemcitabine, reduced tumor volume and improved survival in the study model.
A phase II study of intermittent calcitriol with dexamethasone reported PSA responses in 19% of participants and described the regimen as feasible.
In a clinical series of men with PSA-progressive prostate cancer, some experienced PSA reductions and others had stabilization lasting as long as 36 months.
A randomized presurgical study found dose-dependent increases in prostate vitamin D metabolites and modestly lower PSA with higher-dose vitamin D3.
Calcitriol inhibited Hedgehog signaling, reduced proliferation, promoted differentiation and delayed rhabdomyosarcoma growth in the reported model.
Calcitriol and calcipotriol suppressed osteosarcoma growth and metastasis through a SNAI2 and EMT-associated pathway.
Our Patient Care Team can help you begin a conversation about your diagnosis, current oncology plan, goals, medicines and integrative options used at Sunridge.
14200 N Northsight Blvd #160
Scottsdale, Arizona 85260
Monday–Friday: 9:00 AM–5:00 PM
Saturday: 9:00 AM–12:00 PM
Tell us what you are facing. There is no charge to speak with our Patient Care Team, understand how Sunridge works and determine whether a physician consultation may be an appropriate next step.
This introductory call is not a medical consultation and does not establish a physician-patient relationship.
